Hoppa till innehållet

Alligator Bioscience: BioStock: Orion option exercise triggers milestone payment for Alligator

The collaboration between Alligator Bioscience and the global pharma company Orion Corporation continues to bear fruit. Orion has chosen to exercise its option to develop new antibody cancer therapeutics leveraging Alligator's antibody discovery technologies and RUBY bispecific format.

- With this option exercise, we believe Orion has selected considerably differentiated bispecific antibodies that could lead to highly innovative treatments, says Alligator's CEO Søren Bregenholt.

Read the article at biostock.se:

Orion option exercise triggers milestone payment for Alligator - BioStock (https://www.biostock.se/en/2024/05/orion-option-exercise-triggers-milestone-payment-for-alligator/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Source:Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera